As CD47 also exists in healthy cells, anti-CD47 antibodies may damage these cells and cause potential off-target effects, such as anemia, thrombocytopenia and leukopenia; thus, limiting clinical use [31,32]. The gene discussed is CD47; the disease is Decreased total leukocyte count.